Medicus Pharma (MDCX) Debt to Equity (2025)

Medicus Pharma (MDCX) posted Debt to Equity of -$78.03 for Q4 2025, down 942.06% quarter-over-quarter from -$7.49 in Q3 2025.

Medicus Pharma (MDCX) Debt to Equity (2025) Analysis & Trends

Medicus Pharma (MDCX) has reported Debt to Equity for 1 consecutive years, with -$78.03 the latest figure, recorded in Q4 2025.

Debt to Equity for Q4 2025 came in at -$78.03, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$78.03 (changed N/A YoY), and the FY2025 annual result was -$78.03, changed N/A from the prior year.
Debt to Equity was -$78.03 for Q4 2025 at Medicus Pharma, down from -$7.49 in the prior quarter.
Over five years, Debt to Equity peaked at $1.45 in Q2 2025 and troughed at -$78.03 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	1.39
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	0.68
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	-9.70
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	1.07
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	6.24
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	0.94
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	0.72
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Medicus Pharma	6.91 Mn	-1.69 Mn	-	-78.03

Download Data